Nima Ghalehsari is a Hematology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 40 publications with 328 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-4673Provider last certified this registry record 11 Sept 2025.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20251 payment
- Incyte CorporationProgram year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.7%Aromatase Inhibitor56.7%Anastrozole100%Part D<11 patientsCardiovascular
43.3%ACE inhibitor43.3%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic GVHD after Ptcy Vs. Non-Ptcy Prophylaxis: Incidence, Phenotype, and Outcomes in Matched Donor Transplants
Biology of Blood and Marrow Transplantation
2026 - Accelerated step-up dosing of glofitamab in rapidly progressive R/R DLBCL: a real-world cohort analysis
Blood Immunology & Cellular Therapy
2026 - Prospective cohort study of immunosuppression taper and discontinuation after allogeneic stem cell transplantation
Blood Immunology & Cellular Therapy
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Peter Forsyth, MD
Moffitt Cancer Center
Eric Haura, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”